Program
efimosfermin alfa
Also written as “Efimosfermin alfa”, “Efimosfermin” and “Efimosfermin Alfa”.
In GlaxoSmithKline's pipeline, Fibroblast growth factor 21 (FGF21) analog
. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases, Alcoholic · Obesity, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 97 open or running | phase 3since Oct 15, 2025 | May 5, 2021 | Oct 13, 2027phase 1 · NCT07358546 |
| Novartis | 10 open or running | phase 1since Feb 9, 2018 | Feb 9, 2018 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
efimosfermin alfa GSK6519754
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2018First study: phase 1 study in ObesityNew to NovartisNovartis · NCT03466203 · 61 enrolled · United States
- May 5, 2021GlaxoSmithKline's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to GlaxoSmithKlineGlaxoSmithKline · NCT04880031 · 231 enrolled · United States
- Mar 26, 2025Phase 2 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT06920043 · 42 planned · United States
- Oct 15, 20252 phase 3 studies in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221227, NCT07221188
- Jan 5, 20262 phase 1 studies in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07335198, NCT07358546
- Jul 9, 20262 phase 3 studiesGlaxoSmithKline · NCT07701993, NCT07704892
- Aug 21, 2026Phase 2 study in Liver Diseases, AlcoholicGlaxoSmithKline · NCT07791043 · 274 planned · United States, Argentina, Canada and more
Ahead
- Oct 13, 2027Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07358546
- Mar 24, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221188
- Mar 29, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT07221227
- Jul 3, 2028Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseGlaxoSmithKline · NCT06920043
TargetBeta
“Fibroblast growth factor 21 (FGF21) analog”the company's pipeline, read by Claude · source
Other programs on FGF21
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegozafermin | 89bio-inc | phase 3 | 8 |
| efruxifermin | Novo Nordisk | phase 3 | 6 |
| zalfermin | Novo Nordisk | phase 2 | 10 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07791043Liver Diseases, Alcoholic · United States, Argentina, Canada and more | 2 | Recruiting | GlaxoSmithKline | Aug 11, 2028 | 274 |
| NCT07704892Fibrosis · United States, Japan | 3 | Recruiting | GlaxoSmithKline | Oct 16, 2030 | 380 |
| NCT07701993Fatty Liver · United States, Japan | 3 | Recruiting | GlaxoSmithKline | Jun 23, 2033 | 1,740 |
| NCT07358546Non-alcoholic Fatty Liver Disease · United States | 1 | Recruiting | GlaxoSmithKline | Oct 13, 2027 | 32 |
| NCT07335198Non-alcoholic Fatty Liver Disease · New Zealand | 1 | Completed | GlaxoSmithKline | Aug 13, 2026 | 30 |
| NCT07221227Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more | 3 | Recruiting | GlaxoSmithKline | Mar 29, 2028 | 1,200 |
| NCT07221188Non-alcoholic Fatty Liver Disease · United States, Australia, France and more | 3 | Recruiting | GlaxoSmithKline | Mar 24, 2028 | 1,250 |
| NCT06920043Non-alcoholic Fatty Liver Disease · United States | 2 | Recruiting | GlaxoSmithKline | Jul 3, 2028 | 42 |
| NCT04880031Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | GlaxoSmithKline | Oct 27, 2025 | 231 |
| NCT03466203Obesity · United States | 1 | Completed | Novartis | Nov 13, 2019 | 61 |
How it is read
Names in the registry
- “Efimosfermin alfa”, 7 entries
- “Efimosfermin”, 2 entries
- “Efimosfermin Alfa”, 1 entry
- “LLF580”, 1 entry
Codes read as this program: BOS580.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 6 studies
- Fatty Liver, 2 studies
- Liver Diseases, Alcoholic, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.